XML 35 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity
9 Months Ended
Sep. 30, 2016
Equity  
Equity

 

NOTE 12.  Equity

Common Stock

The following table summarizes the Company’s common stock cash dividends declared in 2016:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amount

 

Dividend

 

Declaration Date

    

Record Date

    

Per Share

    

Payable Date

 

January 28

 

February 8

 

$

0.575

 

February 23

 

April 27

 

May 9

 

 

0.575

 

May 24

 

July 28

 

August 8

 

 

0.575

 

August 23

 

October 31

 

November 10

 

 

0.370

 

November 25

 

 

The following table summarizes the Company’s other common stock activities (shares in thousands):

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30,

 

 

    

2016

    

2015

 

Dividend Reinvestment and Stock Purchase Plan 

 

1,763

 

2,345

 

Conversion of DownREIT units(1) 

 

145

 

75

 

Exercise of stock options 

 

133

 

820

 

Vesting of restricted stock units

 

527

 

382

 

Repurchase of common stock

 

236

 

178

 


(1)

Non-managing member limited liability company (“LLC”) units.

 

Accumulated Other Comprehensive Loss

The following table summarizes the Company’s accumulated other comprehensive loss (in thousands):

 

 

 

 

 

 

 

 

 

 

 

September 30,

 

December 31,

 

 

    

2016

    

2015

 

Cumulative foreign currency translation adjustment

 

$

(21,415)

 

$

(19,485)

 

Unrealized losses on cash flow hedges, net

 

 

(5,556)

 

 

(7,582)

 

Supplemental Executive Retirement Plan minimum liability

 

 

(3,200)

 

 

(3,411)

 

Unrealized gains on available for sale securities

 

 

7

 

 

8

 

Total accumulated other comprehensive loss

 

$

(30,164)

 

$

(30,470)

 

 

Noncontrolling Interests

At September 30, 2016, non-managing members held an aggregate of 4 million units in five limited liability companies (“DownREITs”), for which the Company is the managing member. At September 30, 2016, the carrying and fair values of these DownREIT units were $180 million and $221 million, respectively.

 

On October 7, 2015, the Company issued a 49% noncontrolling interest in HCP Ventures V to an institutional capital investor for $110 million (see Note 3).

 

See Note 15 for the supplemental schedule of non-cash financing activities.